Reviva Pharmaceuticals (RVPH) S-1 6 Oct 22 2022 Q2 IPO registration Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001742927
Entity Registrant Name	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Amendment Flag	false
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	S-1
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-4306526
Entity Address, Address Line One	19925 Stevens Creek Blvd., Suite 10
Entity Address, City or Town	Cupertino
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95014
City Area Code	408
Local Phone Number	501-8881
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets
Cash	$ 19,420,062		$ 29,687,944			$ 8,760,462
Prepaid expenses and other current assets	1,223,399		1,716,057			1,816
Total Assets	20,643,461		31,404,001			8,762,278
Liabilities
Accounts payable	2,553,225		509,583			1,008,046
Accrued expenses and other current liabilities	1,924,157		1,835,228			324,697
Total current liabilities	4,477,382		2,344,811			1,332,743
Warrant liabilities	105,699		372,730			1,963,785
Total Liabilities	4,583,081		2,717,541			3,296,528
Commitments and contingencies (Note 8)
Stockholders' equity
Common stock, par value of $0.0001; 115,000,000 shares authorized; 15,133,286 and 14,433,286 shares issued and outstanding as of June 30, 2022, and December 31, 2021, respectively	1,513		1,443			923
Additional paid-in capital	95,596,548		95,516,986			63,774,920
Accumulated deficit	(79,537,681)		(66,831,969)			(58,310,093)
Total stockholders' equity	16,060,380	$ 21,361,208	28,686,460	$ 34,520,972	$ 4,516,450	5,465,750	$ (6,811,430)
Total Liabilities and Stockholders' Equity	$ 20,643,461		$ 31,404,001			$ 8,762,278

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 14, 2020
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	115,000,000	115,000,000	115,000,000
Common stock, shares issued (in shares)	15,133,286	14,433,286	9,231,737
Common stock, shares outstanding (in shares)	15,133,286	14,433,286	9,231,737	9,231,737

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	11 Months Ended	12 Months Ended
	Dec. 13, 2021	Dec. 31, 2020
Operating expenses
Research and development	$ 4,851,602	$ 295,150
General and administrative	5,252,911	2,139,501
Total operating expenses	10,104,513	2,434,651
Loss from operations	(10,104,513)	(2,434,651)
Other income (expense)
Gain on remeasurement of warrant liabilities	1,591,055	0
Interest and other income (expense), net	(2,414)	105,183
Interest expense	0	(1,453,120)
Total other income (expense), net	1,588,641	(1,347,937)
Loss before provision for income taxes	(8,515,872)	(3,782,588)
Provision for income taxes	6,004	800
Net loss	$ (8,521,876)	$ (3,783,388)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.58)	$ (1.24)
Weighted average shares outstanding Basic and diluted (in shares)	14,790,843	3,061,670

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2019	2,768,346			1,597,585
Balance at Dec. 31, 2019	$ 618	$ 18,644,683	$ (54,526,705)	$ 29,069,974	$ (6,811,430)
Issuance of common stock in lieu of deferred compensation	$ 25	340,907	0	0	340,932
Issuance of common stock in lieu of deferred compensation (in shares)	38,992
Beneficial conversion feature on conversion of notes payable	$ 0	961,680	0	0	961,680
Issuance of common stock upon conversion of notes and accrued interest	$ 110	8,499,233	0	0	8,499,343
Issuance of common stock upon conversion of notes and accrued interest (in shares)	1,099,947
Reclassification of warrant liability	$ 0	1,185,577	0	0	1,185,577
Proceeds from reverse acquisition, net of costs	$ 0	9,375,961	0	$ 0	9,375,961
Effect of reverse recapitalization, net of costs (in shares)	5,324,452			(1,597,585)
Effect of reverse recapitalization, net of costs	$ 170	24,766,879	0	$ (29,069,974)	(4,302,928)
Net loss	$ 0	0	(3,783,388)	$ 0	(3,783,388)
Balance (in shares) at Dec. 31, 2020	9,231,737			0
Balance at Dec. 31, 2020	$ 923	63,774,920	(58,310,093)	$ 0	5,465,750
Net loss	$ 0		(2,557,707)		(2,557,707)
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0		31,497,463
Common stock issued in connection with warrant exercises (in shares)	23,849
Common stock issued in connection with warrant exercises	$ 2	98,375	0		98,377
Stock-based compensation expense	$ 0	17,089	0		17,089
Balance (in shares) at Jun. 30, 2021	13,388,986
Balance at Jun. 30, 2021	$ 1,338	95,387,434	(60,867,800)		34,520,972
Balance (in shares) at Dec. 31, 2020	9,231,737			0
Balance at Dec. 31, 2020	$ 923	63,774,920	(58,310,093)	$ 0	5,465,750
Net loss	$ 0		(8,521,876)		(8,521,876)
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0		31,497,463
Common stock issued in connection with warrant exercises (in shares)	1,057,149
Common stock issued in connection with warrant exercises	$ 106	98,375	0		98,481
Common stock issued to consultant in exchange for services (in shares)	11,000
Common stock issued to consultant in exchange for services	$ 1	39,928	0		39,929
Stock-based compensation expense	$ 0	106,713	0		106,713
Balance (in shares) at Dec. 31, 2021	14,433,286
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)		28,686,460
Balance (in shares) at Mar. 31, 2021	9,231,737
Balance at Mar. 31, 2021	$ 923	63,774,920	(59,259,393)		4,516,450
Net loss	$ 0		(1,608,407)		(1,608,407)
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0		31,497,463
Common stock issued in connection with warrant exercises (in shares)	23,849
Common stock issued in connection with warrant exercises	$ 2	98,375	0		98,377
Stock-based compensation expense	$ 0	17,089	0		17,089
Balance (in shares) at Jun. 30, 2021	13,388,986
Balance at Jun. 30, 2021	$ 1,338	95,387,434	(60,867,800)		34,520,972
Balance (in shares) at Dec. 31, 2021	14,433,286
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)		28,686,460
Net loss	$ 0		(12,705,712)		(12,705,712)
Common stock issued in connection with warrant exercises (in shares)	700,000
Common stock issued in connection with warrant exercises	$ 70	0	0		70
Stock-based compensation expense	$ 0	79,562	0		79,562
Balance (in shares) at Jun. 30, 2022	15,133,286
Balance at Jun. 30, 2022	$ 1,513	95,596,548	(79,537,681)		16,060,380
Balance (in shares) at Mar. 31, 2022	15,133,286
Balance at Mar. 31, 2022	$ 1,513	95,556,672	(74,196,977)		21,361,208
Net loss	0		(5,340,704)		(5,340,704)
Stock-based compensation expense	$ 0	39,876	0		39,876
Balance (in shares) at Jun. 30, 2022	15,133,286
Balance at Jun. 30, 2022	$ 1,513	$ 95,596,548	$ (79,537,681)		$ 16,060,380

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (8,521,876)	$ (3,783,388)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	0	591
Change in fair value of warrant liabilities	(1,591,055)	1,084,052
Noncash interest expense	0	961,680
Issuance of stock in exchange for services	39,929	0
Stock-based compensation expense	106,713	0
Changes in operating assets and liabilities:
Deferred cost	0	(2,330,738)
Prepaid expenses and other current assets	(1,714,241)	0
Accounts payable	(498,463)	775,101
Accrued interest	0	0
Accrued expenses and other current liabilities	1,510,531	(773,922)
Net cash used in operating activities	(10,668,462)	(4,066,624)
Cash flows from financing activities
Issuance of common stock in lieu of deferred compensation	0	340,932
Proceeds from business combination, net of costs	0	9,375,961
Proceeds from issuance of Units in public offering, net	31,497,463	0
Proceeds from issuance of stock upon warrant exercises	98,481	0
Proceeds from issuance of convertible promissory notes	0	3,110,000
Net cash provided by financing activities	31,595,944	12,826,893
Net increase (decrease) in cash	20,927,482	8,760,269
Cash, beginning of period	8,760,462	193
Cash, end of period	29,687,944	8,760,462
Supplemental disclosures of cash flow information:
Cash paid for taxes	2,400	800
Cash paid for interest	0	327,076
Supplemental schedule of noncash financing and investing activities:
Conversion of convertible promissory notes into common stock	0	6,875,088
Payment of certain deferred costs from proceeds from business combination	$ 0	$ 1,000,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets
Cash	$ 19,420,062		$ 29,687,944			$ 8,760,462
Prepaid expenses and other current assets	1,223,399		1,716,057			1,816
Total Assets	20,643,461		31,404,001			8,762,278
Liabilities
Accounts payable	2,553,225		509,583			1,008,046
Accrued expenses and other current liabilities	1,924,157		1,835,228			324,697
Total current liabilities	4,477,382		2,344,811			1,332,743
Warrant liabilities	105,699		372,730			1,963,785
Total Liabilities	4,583,081		2,717,541			3,296,528
Commitments and contingencies (Note 8)
Stockholders' equity
Common stock, par value of $0.0001; 115,000,000 shares authorized; 15,133,286 and 14,433,286 shares issued and outstanding as of June 30, 2022, and December 31, 2021, respectively	1,513		1,443			923
Additional paid-in capital	95,596,548		95,516,986			63,774,920
Accumulated deficit	(79,537,681)		(66,831,969)			(58,310,093)
Total stockholders' equity	16,060,380	$ 21,361,208	28,686,460	$ 34,520,972	$ 4,516,450	5,465,750	$ (6,811,430)
Total Liabilities and Stockholders' Equity	$ 20,643,461		$ 31,404,001			$ 8,762,278

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 14, 2020
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	115,000,000	115,000,000	115,000,000
Common stock, shares issued (in shares)	15,133,286	14,433,286	9,231,737
Common stock, shares outstanding (in shares)	15,133,286	14,433,286	9,231,737	9,231,737

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses
Research and development	$ 4,514,389	$ 374,329	$ 10,344,407	$ 765,490
General and administrative	1,005,099	1,415,773	2,625,238	2,897,540
Total operating expenses	5,519,488	1,790,102	12,969,645	3,663,030
Loss from operations	(5,519,488)	(1,790,102)	(12,969,645)	(3,663,030)
Other income (expense)
Gain on remeasurement of warrant liabilities	178,021	189,146	267,031	1,112,626
Interest and other income (expense), net	7,684	(3,549)	7,452	(3,401)
Total other income (expense), net	185,705	185,597	274,483	1,109,225
Loss before provision for income taxes	(5,333,783)	(1,604,505)	(12,695,162)	(2,553,805)
Provision for income taxes	6,921	3,902	10,550	3,902
Net loss	$ (5,340,704)	$ (1,608,407)	$ (12,705,712)	$ (2,557,707)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.29)	$ (0.12)	$ (0.69)	$ (0.23)
Weighted average shares outstanding
Basic and diluted (in shares)	18,466,586	12,874,961	18,466,586	10,961,449

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	2,768,346
Balance at Dec. 31, 2019	$ 618	$ 18,644,683	$ (54,526,705)	$ (6,811,430)
Net loss	$ 0	0	(3,783,388)	(3,783,388)
Balance (in shares) at Dec. 31, 2020	9,231,737
Balance at Dec. 31, 2020	$ 923	63,774,920	(58,310,093)	5,465,750
Stock-based compensation expense	0	17,089	0	17,089
Net loss	$ 0		(2,557,707)	(2,557,707)
Common stock issued in connection with warrant exercises (in shares)	23,849
Common stock issued in connection with warrant exercises	$ 2	98,375	0	98,377
Balance (in shares) at Jun. 30, 2021	13,388,986
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0	31,497,463
Balance at Jun. 30, 2021	$ 1,338	95,387,434	(60,867,800)	34,520,972
Balance (in shares) at Dec. 31, 2020	9,231,737
Balance at Dec. 31, 2020	$ 923	63,774,920	(58,310,093)	5,465,750
Stock-based compensation expense	0	106,713	0	106,713
Net loss	$ 0		(8,521,876)	(8,521,876)
Common stock issued in connection with warrant exercises (in shares)	1,057,149
Common stock issued in connection with warrant exercises	$ 106	98,375	0	98,481
Balance (in shares) at Dec. 31, 2021	14,433,286
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0	31,497,463
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)	28,686,460
Balance (in shares) at Mar. 31, 2021	9,231,737
Balance at Mar. 31, 2021	$ 923	63,774,920	(59,259,393)	4,516,450
Stock-based compensation expense	0	17,089	0	17,089
Net loss	$ 0		(1,608,407)	(1,608,407)
Common stock issued in connection with warrant exercises (in shares)	23,849
Common stock issued in connection with warrant exercises	$ 2	98,375	0	98,377
Balance (in shares) at Jun. 30, 2021	13,388,986
Issuance of Units in public offering, net (in shares)	4,133,400
Issuance of Units in public offering, net	$ 413	31,497,050	0	31,497,463
Balance at Jun. 30, 2021	$ 1,338	95,387,434	(60,867,800)	34,520,972
Balance (in shares) at Dec. 31, 2021	14,433,286
Balance at Dec. 31, 2021	$ 1,443	95,516,986	(66,831,969)	28,686,460
Stock-based compensation expense	0	79,562	0	79,562
Net loss	$ 0		(12,705,712)	(12,705,712)
Common stock issued in connection with warrant exercises (in shares)	700,000
Common stock issued in connection with warrant exercises	$ 70	0	0	70
Balance (in shares) at Jun. 30, 2022	15,133,286
Balance at Jun. 30, 2022	$ 1,513	95,596,548	(79,537,681)	16,060,380
Balance (in shares) at Mar. 31, 2022	15,133,286
Balance at Mar. 31, 2022	$ 1,513	95,556,672	(74,196,977)	21,361,208
Stock-based compensation expense	0	39,876	0	39,876
Net loss	$ 0		(5,340,704)	(5,340,704)
Balance (in shares) at Jun. 30, 2022	15,133,286
Balance at Jun. 30, 2022	$ 1,513	$ 95,596,548	$ (79,537,681)	$ 16,060,380

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (12,705,712)	$ (2,557,707)
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liabilities	(267,031)	(1,112,626)
Stock-based compensation expense	79,562	17,089
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	661,972	(633,739)
Accounts payable	1,874,328	(649,789)
Accrued expenses and other current liabilities	88,929	479,788
Net cash used in operating activities	(10,267,952)	(4,456,984)
Cash flows from financing activities
Proceeds from Issuance or Sale of Equity, Net	0	31,497,463
Proceeds from issuance of stock upon warrant exercises	70	0
Net cash provided by financing activities	70	31,497,463
Net increase (decrease) in cash	(10,267,882)	27,040,479
Cash, beginning of period	29,687,944	8,760,462
Cash, end of period	19,420,062	35,800,941
Supplemental disclosures of cash flow information:
Cash paid for taxes	3,981	1,600
Deferred offering costs included in accounts payable and other accrued expenses	0	134,355
Prepaid expenses included in accounts payable	$ 169,314	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014.	1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, July 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 8 X. six 30, 2022, not 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, not 10 31, 2021, 10 15, 2022. Liquidity and Going Concern The Company has recognized recurring losses. As of June 30, 2022 three 30, 2022 2021, six 30, 2022 2021, The Company’s current cash on hand is potentially not 12 10 2023. one third not Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may Impact of COVID- 19 In response to the spread of COVID- 19, As a result of the COVID- 19 may 19 may 19 may third The Company is continuing to assess the potential impact of the COVID- 19 June 30, 2022.	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Principals of consolidation The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash are held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may Cash The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of three December 31, 2021, 2020, two may, Property and equipment The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one 1 2 three five Leases In February 2016, 2016 2, Leases (Topic 842 January 1, 2019, no Research and development costs Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not General and administrative costs General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not Income taxes The Company utilizes FASB ASC 740, not” not The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% not Stock-based compensation Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC 718 The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under: • Expected term ​ • Expected volatility ​ • Expected dividend no ​ • Risk-free interest rate zero ​ • Forfeiture rate one As of January 1, 2019, No. 2018 07, 718 not not Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values. Fair Value Measurements of Warrants ASC 820 820 820 1 2 three 1 3 The three 820 • Level 1 — Quoted 1 ​ • Level 2 — Directly not 2 not ​ • Level 3 — Unobservable no ​ In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Beneficial Conversion Features In accordance with FASB ASC 470 20,

Note 3 - Public Offering

Note 3 - Public Offering	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]		10. STOCKHOLDERS EQUITY (DEFICIT) Our authorized capital stock consists of: ● 115,000,000 shares of common stock, par value $0.0001 per share; and ● 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2021, November 2021, September 2020, Common Stock Voting. The holders of our common stock are entitled to one Dividends. The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock. Liquidation Rights. In the event of the Company’s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock. Conversion Right. The holders of common stock have no Preemptive and Similar Rights. The holders of common stock have no Redemption/Put Rights. There are no Preferred Stock Our board of directors has the authority to issue shares of preferred stock from time to time on terms it may one Warrants As of December 31, 2021, Each public warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 No We may not of $0.01 ● if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third ● if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 ● at any time while the public warrants are exercisable, ● upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; ● are exercisable for cash or on a cashless basis, at the holder’s option ● cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. ● The redemption price is to be calculated as the 10 one In no The Company classified the private warrants pursuant to ASC 815 December 31, 2021 December 31, 2021, The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of December 31, 2021, December 31, 2020. In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one June 1, 2026. December 31, 2021, no Common stock warrants 2020 In July 2020, five “2020 2020 2020 Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 % The 2020 December 31, 2020. 2016 The Company issued warrants in connection with the 2016 “2016 April 28, 2022. The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was not In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268. Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be zero not not Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending December 31, 2020. Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC 480,
IPO [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	3. PUBLIC OFFERING On June 1, 2021, one one one one one one no not one one one one	3. PUBLIC OFFERING On June 1, 2021, one one one one one one one no not one one one one

Note 4 - Business Combination

Note 4 - Business Combination	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. BUSINESS COMBINATION On December 14, 2020, July 20, 2020 Upon the closing of the Business Combination, all shares of Reviva Pharmaceuticals, Inc. common stock and preferred stock issuance and outstanding immediately prior to the Business Combination converted into common stock of Reviva Pharmaceuticals Holdings, Inc., with a par value of $0.0001 per share at an exchange rate of 0.152268 for common stock and 0.414647 for preferred stock. Each issued and outstanding warrant to acquire shares of Reviva Pharmaceuticals, Inc. common stock were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into a warrant for Reviva Pharmaceuticals Holdings, Inc. common stock, with its price and number of shares adjusted based on the common stock exchange rate of 0.152268. 0.152268. In addition to the merger consideration set forth above, the Reviva Pharmaceuticals, Inc. Security holders also have a contingent right to receive up to an additional 1,000,000 shares of Reviva Pharmaceuticals Holdings, Inc. (the “Earnout Shares”) based on the stock price performance of the common stock and the achievement by the Company of certain clinical trial milestones during the three ● the closing price of the Company’s common stock has to be equal to or greater than $15.00 per share for any 20 trading days within any 30 trading day period; and ● the Company must receive positive data from (i) its first 3 2 The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing is treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the holders of Reviva Pharmaceuticals, Inc. having a majority of the voting power of the post-combination company, Reviva Pharmaceuticals, Inc. senior management comprising substantially all of the senior management of the post-combination company, the relative size of Reviva compared to Tenzing, and Reviva Pharmaceuticals, Inc. operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Reviva Pharmaceuticals, Inc. issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing are stated at historical cost, with no goodwill or other intangible assets recorded. The accompanying financial statements and related notes reflect the historical results of Reviva Pharmaceuticals, Inc. prior to the merger and do not

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following: December 31, 2021 2020 Computer equipment $ 32,500 $ 32,500 Furniture and fixtures 9,208 9,208 Accumulated depreciation (41,708 ) (41,708 ) Property and equipment, net $ — $ — Depreciation expense for the years ended December 31, 2021 2020

Note 6 - Employee Benefit Plan

Note 6 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	6. EMPLOYEE BENEFIT PLAN In 2014, 401 December 31, 2021.

Note 7 - Convertible Promissory

Note 7 - Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	7. CONVERTIBLE PROMISSORY NOTES 2016 From June 2016 April 2017, “2016 2016 not Interest was initially accrued at 8% per annum and was scheduled to be paid in cash at maturity date. The 2016 twelve 2016 2017 December 31, 2019, The original stated conversion term for the 2016 not 20% $85 2016 On December 10, 2020, 2016 2016 one no 2016 none. On January 2, 2020, 2016 2016 2018 From November 2018 January 2019, “2018 2018 not 2018 Additionally, the holders of the 2018 “2018 December 31, 2019. Interest on the 2018 2018 six six 2018 six 2018 On December 10, 2020, 2018 2018 2018 $50,000 2018 2018 $50,000 2018 no 2018 2020 From March May 2020, “2020 2020 not 2020 Additionally, the holders of the 2020 “2020 2020 2020 “2020 On December 10, 2020, 2020 2020 2020 $50,000 2020 2020 $50,000 2020 no 2020 Between August 2020 October 2020, In addition, the Company entered into a contingent capital commitment with certain investors for $2,000,000 (“Reviva Contingent Interim Period Notes”) that became effective upon consummation of the Business Combination. The Reviva Contingent Interim Period Notes were interest free. The Reviva Contingent Interim Period Notes provided that the notes automatically converted, immediately prior to consummation of the Business Combination, into 1,718,280 shares of Reviva common stock at a conversion price equal to $1.163953. On consummation of the Business Combination, these shares converted into 261,626 shares of the Company’s common stock. The holders have no

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. INCOME TAXES As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, there was no December 31, 2021 2020. Reconciliations to the statutory federal income tax rate and the Company's effective tax rate consist of the following: Year Ended December 31, 2021 2020 Statutory federal income tax rate $ (1,788,135 ) $ (794,343 ) State income taxes, net of federal tax benefits (58,152 ) (114,864 ) Stock-based compensation 8,924 — Foreign rate differential 1,414 (45 ) Warrant expense (334,122 ) 227,651 Beneficial conversion feature related to notes — 201,953 Other permanent differences 5,301 19,204 Valuation allowance 2,173,051 461,244 $ 8,281 $ 800 The components of deferred tax assets included on the balance sheet are: December 31, 2021 2020 NOL carryforwards $ 11,262,916 $ 9,177,607 Accruals and reserves 81,911 10,898 Stock compensation 197,508 237,976 Fixed assets/capitalized start-up costs 2,557 3,332 11,544,892 9,429,813 Valuation allowance (11,544,892 ) (9,429,813 ) Net deferred tax assets — — Deferred income taxes $ — $ — The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The total increase in valuation allowance is $2,115,079 for the year ending December 31, 2021. The Company currently has net operating loss carryforwards of approximately $49.2 million and $13.2 million for U.S. Federal and state purposes respectively. Approximately $35.3 million of the U.S. federal losses begin to expire in 2029. 2018 may 100% As of December 31, 2021 2020, The Tax Reform Act of 1986 The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense. As of December 31, 2021 2020, The Company’s income tax returns for all years remain open to examination by federal and state taxing authorities. The Company does not 12 As of December 31, 2021 2020, On March 27, 2020, 2019 2020 2019 2020. 163 30% 50% no

Note 9 - Loss Per Share

Note 9 - Loss Per Share	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	5. LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. Diluted loss per share includes potentially dilutive securities such as stock options, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per shares for the three six 30, 2022 30, 2021 The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: Three Months Ended Six Months Ended June 30, 2022 2021 2022 2021 Shares issuable upon exercise of stock options 192,898 146,698 192,898 146,698 Shares issuable upon exercise of warrants to purchase common stock 13,883,732 13,883,732 13,883,732 13,883,732 Shares contingently issuable for earnout 1,000,000 1,000,000 1,000,000 1,000,000 15,076,630 15,030,430 15,076,630 15,030,430 The diluted loss per share computation equals basic loss per share for the three six 30, 2022 30, 2021	9. LOSS PER SHARE Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share is calculated based on the weighted average shares of common stock then outstanding. Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the 9,231,737 shares of common stock outstanding immediately after the reverse recapitalization in connection with the Business Combination and assumes these shares have been outstanding as of the beginning of the earliest period presented. For the years ended December 31, 2021 2020, 11, not

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. STOCKHOLDERS EQUITY (DEFICIT) Our authorized capital stock consists of: ● 115,000,000 shares of common stock, par value $0.0001 per share; and ● 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2021, November 2021, September 2020, Common Stock Voting. The holders of our common stock are entitled to one Dividends. The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock. Liquidation Rights. In the event of the Company’s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock. Conversion Right. The holders of common stock have no Preemptive and Similar Rights. The holders of common stock have no Redemption/Put Rights. There are no Preferred Stock Our board of directors has the authority to issue shares of preferred stock from time to time on terms it may one Warrants As of December 31, 2021, Each public warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 No We may not of $0.01 ● if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third ● if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 ● at any time while the public warrants are exercisable, ● upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; ● are exercisable for cash or on a cashless basis, at the holder’s option ● cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. ● The redemption price is to be calculated as the 10 one In no The Company classified the private warrants pursuant to ASC 815 December 31, 2021 December 31, 2021, The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of December 31, 2021, December 31, 2020. In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one June 1, 2026. December 31, 2021, no Common stock warrants 2020 In July 2020, five “2020 2020 2020 Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 % The 2020 December 31, 2020. 2016 The Company issued warrants in connection with the 2016 “2016 April 28, 2022. The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was not In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268. Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be zero not not Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending December 31, 2020. Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC 480,

Note 11 - Stock Option Plan and

Note 11 - Stock Option Plan and Stock-based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. STOCK OPTION PLANS AND STOCK-BASED COMPENSATION Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the three 30, 2022 2021, six 30, 2022, 2021, 30, 2022, Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero Dividend Yield – The Company has not not No 2022 30, 2022. Activity under the stock plans for the six June 30, 2022, Shares Number of Outstanding Weighted Weighted Balance, December 31, 2021 1,257,334 192,898 $ 8.46 6.76 Balance, June 30, 2022 1,257,334 192,898 $ 8.46 6.27 Balance at June 30, 2022 192,898 $ 8.46 6.27 Options exercisable at June 30, 2022 112,744 $ 11.51 4.30	11. STOCK OPTION PLAN AND STOCK-BASED COMPENSATION 2006 Reviva’s board of directors adopted, and Reviva’s stockholders approved, the Reviva Pharmaceuticals, Inc. 2006 August 2006. 2006 422 not 2016, no 2006 Upon the Business Combination, the Reviva Pharmaceuticals, Inc. 2006 2006 “2006 2006 2006 no 2006 2020 On December 14, 2020, 2020 “2020 2020 may As of December 31, 2021, may 2020 January 1st not ten January 1st 2020 January 1, 2030, ten December 31st 2020 may Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the years ended December 31, 2021 2020, December 31, 2021, 2020, Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero Dividend Yield – The Company has not not The assumptions used in estimating the fair value of options granted in 2021 Expected Term in years - 5.20 - 6.08 Volatility – 87.1% - 93.9% Risk-free interest rate – 0.95% - 1.31% Dividend Yield – 0.00% The Company granted no stock options during the year ended December 31, 2020. Activity under the stock plans for the years ending December 31, 2020 2021 Shares Available for Grant Number of Options Outstanding Weighted Average Exercise Price per Share Balance, December 31, 2019 343,871 112,932 $ 15.37 Options authorized 461,587 — $ — Options cancelled 47,461 (47,461 ) $ — Effect of plan amendment on business combination (391,332 ) — $ — Balance, December 31, 2020 461,587 65,471 $ 16.86 Options authorized 923,174 — $ — Options granted (127,427 ) 127,427 $ 4.14 Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Vested and expected to vest, December 31, 2021 192,898 $ 8.46 Options outstanding under the stock plans are as follows as of December 31, 2021: Options Outstanding Weighted Average Remaining Contractual Life (Years) Options Exercisable Weighted Average Exercise Prices per Share 48,724 0.85 48,724 $ 11.89 16,747 2.93 16,747 $ 31.33 81,227 9.31 17,832 $ 4.38 46,200 9.89 12,500 $ 3.72 192,898 6.76 95,803 $ 8.46

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, 1 third not 30 Indemnification From time to time, in its normal course of business, the Company may may third not no Operating Leases The Company adopted ASC 842 1, 2020. one twelve 19925 100, 95014. 2021 1, 2022, 12	12. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, 2 may third not may 30 Indemnification From time to time, in its normal course of business, the Company may may third may not no may Operating Leases The Company adopted ASC 842 January 1, 2020. one twelve 19925 100, 95014. February 1, 2021,

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	13. SUBSEQUENT EVENTS In January 2022, may not

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Operations	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014.	1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, July 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 8 X. six 30, 2022, not 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, not 10 31, 2021, 10 15, 2022. Liquidity and Going Concern The Company has recognized recurring losses. As of June 30, 2022 three 30, 2022 2021, six 30, 2022 2021, The Company’s current cash on hand is potentially not 12 10 2023. one third not Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may Impact of COVID- 19 In response to the spread of COVID- 19, As a result of the COVID- 19 may 19 may 19 may third The Company is continuing to assess the potential impact of the COVID- 19 June 30, 2022.	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Principals of consolidation The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash are held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may Cash The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of three December 31, 2021, 2020, two may, Property and equipment The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one 1 2 three five Leases In February 2016, 2016 2, Leases (Topic 842 January 1, 2019, no Research and development costs Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not General and administrative costs General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not Income taxes The Company utilizes FASB ASC 740, not” not The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% not Stock-based compensation Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC 718 The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under: • Expected term ​ • Expected volatility ​ • Expected dividend no ​ • Risk-free interest rate zero ​ • Forfeiture rate one As of January 1, 2019, No. 2018 07, 718 not not Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values. Fair Value Measurements of Warrants ASC 820 820 820 1 2 three 1 3 The three 820 • Level 1 — Quoted 1 ​ • Level 2 — Directly not 2 not ​ • Level 3 — Unobservable no ​ In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Beneficial Conversion Features In accordance with FASB ASC 470 20,

Note 3 - Public Offering_2

Note 3 - Public Offering	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]		10. STOCKHOLDERS EQUITY (DEFICIT) Our authorized capital stock consists of: ● 115,000,000 shares of common stock, par value $0.0001 per share; and ● 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2021, November 2021, September 2020, Common Stock Voting. The holders of our common stock are entitled to one Dividends. The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock. Liquidation Rights. In the event of the Company’s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock. Conversion Right. The holders of common stock have no Preemptive and Similar Rights. The holders of common stock have no Redemption/Put Rights. There are no Preferred Stock Our board of directors has the authority to issue shares of preferred stock from time to time on terms it may one Warrants As of December 31, 2021, Each public warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 No We may not of $0.01 ● if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third ● if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 ● at any time while the public warrants are exercisable, ● upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; ● are exercisable for cash or on a cashless basis, at the holder’s option ● cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. ● The redemption price is to be calculated as the 10 one In no The Company classified the private warrants pursuant to ASC 815 December 31, 2021 December 31, 2021, The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of December 31, 2021, December 31, 2020. In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one June 1, 2026. December 31, 2021, no Common stock warrants 2020 In July 2020, five “2020 2020 2020 Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 % The 2020 December 31, 2020. 2016 The Company issued warrants in connection with the 2016 “2016 April 28, 2022. The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was not In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268. Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be zero not not Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending December 31, 2020. Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC 480,
IPO [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	3. PUBLIC OFFERING On June 1, 2021, one one one one one one no not one one one one	3. PUBLIC OFFERING On June 1, 2021, one one one one one one one no not one one one one

Note 4 - At the Market Offering

Note 4 - At the Market Offering	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
At the Market Offering [Text Block]	4. AT THE MARKET OFFERING In January 2022, Effective July 28, 2022, June 30, 2022, not

Note 5 - Loss Per Share

Note 5 - Loss Per Share	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	5. LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. Diluted loss per share includes potentially dilutive securities such as stock options, warrants to purchase common stock, and other convertible instruments unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per shares for the three six 30, 2022 30, 2021 The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: Three Months Ended Six Months Ended June 30, 2022 2021 2022 2021 Shares issuable upon exercise of stock options 192,898 146,698 192,898 146,698 Shares issuable upon exercise of warrants to purchase common stock 13,883,732 13,883,732 13,883,732 13,883,732 Shares contingently issuable for earnout 1,000,000 1,000,000 1,000,000 1,000,000 15,076,630 15,030,430 15,076,630 15,030,430 The diluted loss per share computation equals basic loss per share for the three six 30, 2022 30, 2021	9. LOSS PER SHARE Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share is calculated based on the weighted average shares of common stock then outstanding. Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the 9,231,737 shares of common stock outstanding immediately after the reverse recapitalization in connection with the Business Combination and assumes these shares have been outstanding as of the beginning of the earliest period presented. For the years ended December 31, 2021 2020, 11, not

Note 6 - Warrants

Note 6 - Warrants	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Warrants [Text Block]	6. WARRANTS As of June 30, 2022, Each public warrant entitles the holder thereof to purchase one No We may not • if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the third • if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 • at any time while the public warrants are exercisable • upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; • are exercisable for cash or on a cashless basis, at the holder’s option • cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. • The redemption price is to be calculated as the 10 one In no The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of June 30, 2022, 31, 2021. In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0 million and the Pre-Funded Warrants are exercisable into one share of common stock at an exercise price of $0.0001 per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for 6,900,000 shares of common stock with an exercise price of $4.125 per share of common stock any time after issuance. The Investor Warrants expire on June 1, 2026. six 30, 2022. no

Note 7 - Stock Option Plan and

Note 7 - Stock Option Plan and Stock-based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. STOCK OPTION PLANS AND STOCK-BASED COMPENSATION Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the three 30, 2022 2021, six 30, 2022, 2021, 30, 2022, Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero Dividend Yield – The Company has not not No 2022 30, 2022. Activity under the stock plans for the six June 30, 2022, Shares Number of Outstanding Weighted Weighted Balance, December 31, 2021 1,257,334 192,898 $ 8.46 6.76 Balance, June 30, 2022 1,257,334 192,898 $ 8.46 6.27 Balance at June 30, 2022 192,898 $ 8.46 6.27 Options exercisable at June 30, 2022 112,744 $ 11.51 4.30	11. STOCK OPTION PLAN AND STOCK-BASED COMPENSATION 2006 Reviva’s board of directors adopted, and Reviva’s stockholders approved, the Reviva Pharmaceuticals, Inc. 2006 August 2006. 2006 422 not 2016, no 2006 Upon the Business Combination, the Reviva Pharmaceuticals, Inc. 2006 2006 “2006 2006 2006 no 2006 2020 On December 14, 2020, 2020 “2020 2020 may As of December 31, 2021, may 2020 January 1st not ten January 1st 2020 January 1, 2030, ten December 31st 2020 may Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the years ended December 31, 2021 2020, December 31, 2021, 2020, Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term – Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero Dividend Yield – The Company has not not The assumptions used in estimating the fair value of options granted in 2021 Expected Term in years - 5.20 - 6.08 Volatility – 87.1% - 93.9% Risk-free interest rate – 0.95% - 1.31% Dividend Yield – 0.00% The Company granted no stock options during the year ended December 31, 2020. Activity under the stock plans for the years ending December 31, 2020 2021 Shares Available for Grant Number of Options Outstanding Weighted Average Exercise Price per Share Balance, December 31, 2019 343,871 112,932 $ 15.37 Options authorized 461,587 — $ — Options cancelled 47,461 (47,461 ) $ — Effect of plan amendment on business combination (391,332 ) — $ — Balance, December 31, 2020 461,587 65,471 $ 16.86 Options authorized 923,174 — $ — Options granted (127,427 ) 127,427 $ 4.14 Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Vested and expected to vest, December 31, 2021 192,898 $ 8.46 Options outstanding under the stock plans are as follows as of December 31, 2021: Options Outstanding Weighted Average Remaining Contractual Life (Years) Options Exercisable Weighted Average Exercise Prices per Share 48,724 0.85 48,724 $ 11.89 16,747 2.93 16,747 $ 31.33 81,227 9.31 17,832 $ 4.38 46,200 9.89 12,500 $ 3.72 192,898 6.76 95,803 $ 8.46

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, 1 third not 30 Indemnification From time to time, in its normal course of business, the Company may may third not no Operating Leases The Company adopted ASC 842 1, 2020. one twelve 19925 100, 95014. 2021 1, 2022, 12	12. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, 2 may third not may 30 Indemnification From time to time, in its normal course of business, the Company may may third may not no may Operating Leases The Company adopted ASC 842 January 1, 2020. one twelve 19925 100, 95014. February 1, 2021,

Note 9 Fair Value Measurements

Note 9 Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: • Level 1 • Level 2 • Level 3 The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company’s warrant liabilities required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of June 30, 2022 31, 2021: June 30, 2022 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability — — 105,699 105,699 Total $ — $ — $ 105,699 $ 105,699 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ 372,730 $ 372,730 Total $ — $ — $ 372,730 $ 372,730 The following table summarizes the changes in the fair value of the warrant liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Balance, beginning of period $ 283,720 1,040,305 372,730 1,963,785 Change in fair value of warrant liability (178,021 ) (189,146 ) (267,031 ) (1,112,626 ) Balance, end of period $ 105,699 $ 851,159 $ 105,699 $ 851,159 The Company classified the private warrants pursuant to ASC 815 30, 2022 three six 30, 2022,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10 8 X. six 30, 2022, not 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, not 10 31, 2021, 10 15, 2022.	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity.
Consolidation, Policy [Policy Text Block]		Principals of consolidation The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash is held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may	Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company’s cash are held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of three December 31, 2021, 2020, two may,
Property, Plant and Equipment, Policy [Policy Text Block]		Property and equipment The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one 1 2 three five
Lessee, Leases [Policy Text Block]		Leases In February 2016, 2016 2, Leases (Topic 842 January 1, 2019, no
Research and Development Expense, Policy [Policy Text Block]		Research and development costs Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not
Selling, General and Administrative Expenses, Policy [Policy Text Block]		General and administrative costs General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not
Income Tax, Policy [Policy Text Block]		Income taxes The Company utilizes FASB ASC 740, not” not The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% not
Share-Based Payment Arrangement [Policy Text Block]		Stock-based compensation Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC 718 The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under: • Expected term ​ • Expected volatility ​ • Expected dividend no ​ • Risk-free interest rate zero ​ • Forfeiture rate one As of January 1, 2019, No. 2018 07, 718 not not
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value Measurements of Warrants ASC 820 820 820 1 2 three 1 3 The three 820 • Level 1 — Quoted 1 ​ • Level 2 — Directly not 2 not ​ • Level 3 — Unobservable no ​ In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
Beneficial Conversion Feature [Policy Text Block]		Beneficial Conversion Features In accordance with FASB ASC 470 20,
Going Concern [Policy Text Block]	Liquidity and Going Concern The Company has recognized recurring losses. As of June 30, 2022 three 30, 2022 2021, six 30, 2022 2021, The Company’s current cash on hand is potentially not 12 10 2023. one third not
Impact of COVID-19 [Policy Text Block]	Impact of COVID- 19 In response to the spread of COVID- 19, As a result of the COVID- 19 may 19 may 19 may third The Company is continuing to assess the potential impact of the COVID- 19 June 30, 2022.

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2021 2020 Computer equipment $ 32,500 $ 32,500 Furniture and fixtures 9,208 9,208 Accumulated depreciation (41,708 ) (41,708 ) Property and equipment, net $ — $ —

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 Statutory federal income tax rate $ (1,788,135 ) $ (794,343 ) State income taxes, net of federal tax benefits (58,152 ) (114,864 ) Stock-based compensation 8,924 — Foreign rate differential 1,414 (45 ) Warrant expense (334,122 ) 227,651 Beneficial conversion feature related to notes — 201,953 Other permanent differences 5,301 19,204 Valuation allowance 2,173,051 461,244 $ 8,281 $ 800
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2021 2020 NOL carryforwards $ 11,262,916 $ 9,177,607 Accruals and reserves 81,911 10,898 Stock compensation 197,508 237,976 Fixed assets/capitalized start-up costs 2,557 3,332 11,544,892 9,429,813 Valuation allowance (11,544,892 ) (9,429,813 ) Net deferred tax assets — — Deferred income taxes $ — $ —

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 %

Note 11 - Stock Option Plan a_2

Note 11 - Stock Option Plan and Stock-based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Number of Outstanding Weighted Weighted Balance, December 31, 2021 1,257,334 192,898 $ 8.46 6.76 Balance, June 30, 2022 1,257,334 192,898 $ 8.46 6.27 Balance at June 30, 2022 192,898 $ 8.46 6.27 Options exercisable at June 30, 2022 112,744 $ 11.51 4.30	Shares Available for Grant Number of Options Outstanding Weighted Average Exercise Price per Share Balance, December 31, 2019 343,871 112,932 $ 15.37 Options authorized 461,587 — $ — Options cancelled 47,461 (47,461 ) $ — Effect of plan amendment on business combination (391,332 ) — $ — Balance, December 31, 2020 461,587 65,471 $ 16.86 Options authorized 923,174 — $ — Options granted (127,427 ) 127,427 $ 4.14 Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Vested and expected to vest, December 31, 2021 192,898 $ 8.46
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]		Options Outstanding Weighted Average Remaining Contractual Life (Years) Options Exercisable Weighted Average Exercise Prices per Share 48,724 0.85 48,724 $ 11.89 16,747 2.93 16,747 $ 31.33 81,227 9.31 17,832 $ 4.38 46,200 9.89 12,500 $ 3.72 192,898 6.76 95,803 $ 8.46

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Six Months Ended June 30, 2022 2021 2022 2021 Shares issuable upon exercise of stock options 192,898 146,698 192,898 146,698 Shares issuable upon exercise of warrants to purchase common stock 13,883,732 13,883,732 13,883,732 13,883,732 Shares contingently issuable for earnout 1,000,000 1,000,000 1,000,000 1,000,000 15,076,630 15,030,430 15,076,630 15,030,430

Note 7 - Stock Option Plan an_2

Note 7 - Stock Option Plan and Stock-based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Number of Outstanding Weighted Weighted Balance, December 31, 2021 1,257,334 192,898 $ 8.46 6.76 Balance, June 30, 2022 1,257,334 192,898 $ 8.46 6.27 Balance at June 30, 2022 192,898 $ 8.46 6.27 Options exercisable at June 30, 2022 112,744 $ 11.51 4.30	Shares Available for Grant Number of Options Outstanding Weighted Average Exercise Price per Share Balance, December 31, 2019 343,871 112,932 $ 15.37 Options authorized 461,587 — $ — Options cancelled 47,461 (47,461 ) $ — Effect of plan amendment on business combination (391,332 ) — $ — Balance, December 31, 2020 461,587 65,471 $ 16.86 Options authorized 923,174 — $ — Options granted (127,427 ) 127,427 $ 4.14 Balance, December 31, 2021 1,257,334 192,898 $ 8.46 Vested and expected to vest, December 31, 2021 192,898 $ 8.46

Note 9 Fair Value Measurements

Note 9 Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2022 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability — — 105,699 105,699 Total $ — $ — $ 105,699 $ 105,699 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ — $ — $ 372,730 $ 372,730 Total $ — $ — $ 372,730 $ 372,730
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Balance, beginning of period $ 283,720 1,040,305 372,730 1,963,785 Change in fair value of warrant liability (178,021 ) (189,146 ) (267,031 ) (1,112,626 ) Balance, end of period $ 105,699 $ 851,159 $ 105,699 $ 851,159

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)	12 Months Ended
	Dec. 31, 2021
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years

Note 3 - Public Offering (Detai

Note 3 - Public Offering (Details Textual) - USD ($)		3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 01, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Proceeds from Issuance or Sale of Equity, Net			$ 0	$ 31,497,463
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,133,400		4,133,400	4,133,400
Public Offering [Member]
Number of Units, One, Issued (in shares)	4,133,400
Number of Units, Two, Issued (in shares)	5,066,600
Shares Issued, Price Per Share, One (in dollars per share)	$ 3.75
Shares Issued, Price Per Share, Two (in dollars per share)	$ 3.7499
Proceeds from Issuance or Sale of Equity, Net	$ 31,500,000
Payments of Stock Issuance Costs	$ 3,000,000
Public Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,133,400
Over-Allotment Option [Member]
Number of Units, One, Issued (in shares)	1,200,000
Pre-Funded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600	5,066,600		5,066,600	1,033,300
Investor Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.125
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000

Note 4 - Business Combination (

Note 4 - Business Combination (Details Textual) $ / shares in Units, $ in Thousands	Dec. 14, 2020 USD ($) $ / shares shares	Jun. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.0001
Reviva Pharmaceuticals, Inc. [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Additional Shares to be Issued to Security Holders, Contingent on Stock Price Performance (in shares) | shares	1,000,000
Stock Price Performance, Milestone Period (Year)	3 years
Threshold Closing Price for Specified Number of Trading Days (in dollars per share)	$ 15
Threshold Trading Days for Sale of Shares (Day)	20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)	30 days
Goodwill, Ending Balance | $	$ 0
Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Common Stock into Company's Common Stock [Member]
Conversion of Stock, Conversion Rate	0.152268
Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Preferred Stock into Company's Common Stock [Member]
Conversion of Stock, Conversion Rate	0.414647

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Total	$ 0	$ 591

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($)	Dec. 13, 2021	Dec. 31, 2020
Accumulated depreciation	$ (41,708)	$ (41,708)
Property and equipment, net	0	0
Computer Equipment [Member]
Property, Plant and Equipment, Gross	32,500	32,500
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	$ 9,208	$ 9,208

Note 6 - Employee Benefit Plan

Note 6 - Employee Benefit Plan (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 7 - Convertible Promisso_2

Note 7 - Convertible Promissory Notes (Details Textual) - USD ($)						3 Months Ended
	Dec. 14, 2020	Dec. 10, 2020	Jan. 02, 2020	Nov. 01, 2018	Jun. 01, 2016	Oct. 31, 2020	Dec. 31, 2020	Dec. 15, 2020	Aug. 01, 2020	Mar. 01, 2020	Dec. 31, 2019
The 2018 Contingent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants and Rights Outstanding											$ 0
The 2020 Contingent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)										5 years
Warrants and Rights Outstanding							$ 0
Conversion of 2016 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	576,836
Conversion of 2018 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	56,461
Conversion of 2020 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	113,422
Conversion of Reviva Contingent Interim Period Note into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)		261,626
Conversion of 2016 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		3,788,461
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.329698
Conversion of 2018 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		370,811
Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.831018
Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.330045
Conversion of 2020 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		744,916
Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.831009
Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.329770
Conversion of August 2020 to October 2020 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						601,632
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.831063
Conversion of Reviva Contingent Interim Period Note into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						1,718,280
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 1.163953
The 2016 Notes [Member]
Debt Instrument, Face Amount					$ 4,795,088
Qualified Financing, Minimum Threshold					$ 5,000,000
Qualified Financing, Discount Rate to Price Paid by Investors					20%
Pre-offering Valuation Prior to Qualified Financing Event					$ 85,000,000
Debt Instrument, Interest Rate, Stated Percentage					8%
Debt Instrument, Term (Month)					12 months
Debt Instrument, Debt Default, Interest Rate							12%
Convertible Notes Payable, Total		$ 1,200,000	$ 1,200,000								3,490,087
Interest Payable											$ 1,192,496
Debt Instrument, Convertible, Beneficial Conversion Feature		0
Warrants and Rights Outstanding	$ 7,395
The 2016 Notes [Member] | One Investor [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Interest Payable, Current			$ 242,236					$ 79,840
Debt Instrument, Fee Amount			5,000
Repayments of Convertible Debt			$ 1,447,236
The 2018 Notes [Member]
Debt Instrument, Face Amount				$ 275,000
Qualified Financing, Discount Rate to Price Paid by Investors				20%
Debt Instrument, Interest Rate, Stated Percentage				8%
Debt Instrument, Term (Month)				6 months
Debt Instrument, Debt Default, Interest Rate							8%
Debt Instrument, Convertible, Beneficial Conversion Feature		159,025
Debt Instrument, Renewal Term (Month)				6 months
The 2020 Notes [Member]
Debt Instrument, Face Amount										$ 610,000
Qualified Financing, Discount Rate to Price Paid by Investors										20%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 317,730
August 2020 to October 2020 Notes [Member]
Debt Instrument, Face Amount									$ 500,000
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 274,083
Reviva Contingent Interim Period Note [Member]
Debt Instrument, Face Amount									$ 2,000,000
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 210,842

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2,115,079
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0	0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	49,200,000
Operating Loss Carryforwards, Subject to Expiration	35,300,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 13,200,000

Note 8 - Income Taxes - Provisi

Note 8 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		11 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 13, 2021	Dec. 31, 2021	Dec. 31, 2020
Statutory federal income tax rate						$ (1,788,135)	$ (794,343)
State income taxes, net of federal tax benefits						(58,152)	(114,864)
Stock-based compensation						8,924	0
Foreign rate differential						1,414	(45)
Warrant expense						(334,122)	227,651
Beneficial conversion feature related to notes						0	201,953
Other permanent differences						5,301	19,204
Valuation allowance						2,173,051	461,244
Income Tax Expense (Benefit), Total	$ 6,921	$ 3,902	$ 10,550	$ 3,902	$ 6,004	$ 8,281	$ 800

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
NOL carryforwards	$ 11,262,916	$ 9,177,607
Accruals and reserves	81,911	10,898
Stock compensation	197,508	237,976
Fixed assets/capitalized start-up costs	2,557	3,332
Deferred Tax Assets, Gross, Total	11,544,892	9,429,813
Valuation allowance	(11,544,892)	(9,429,813)
Net deferred tax assets	0	0
Deferred income taxes	$ 0	$ 0

Note 9 - Loss Per Share (Detail

Note 9 - Loss Per Share (Details Textual) - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 14, 2020
Common Stock, Shares, Outstanding, Ending Balance (in shares)	15,133,286		15,133,286		14,433,286	9,231,737	9,231,737
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	15,076,630	15,030,430	15,076,630	15,030,430
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	13,883,732	13,883,732	13,883,732	13,883,732	13,883,732	7,007,581
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	192,898	146,698	192,898	146,698	192,898	65,471
Earn-out Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity (Deficit) (Details Textual)		1 Months Ended		3 Months Ended		6 Months Ended		11 Months Ended	12 Months Ended
	Jun. 01, 2021 USD ($) $ / shares shares	Nov. 30, 2021 shares	Sep. 30, 2020 shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Dec. 13, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 14, 2020 USD ($) shares	Jul. 31, 2020 USD ($) $ / shares shares	Jun. 01, 2016 USD ($) $ / shares shares
Common Stock, Shares Authorized (in shares)				115,000,000		115,000,000			115,000,000	115,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.0001		$ 0.0001			$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized (in shares)									10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.0001
Common Stock, Shares, Outstanding, Ending Balance (in shares)				15,133,286		15,133,286			14,433,286	9,231,737	9,231,737
Preferred Stock, Shares Outstanding, Ending Balance (in shares)									0
Stock Issued During Period, Shares, Issued for Services (in shares)		11,000
Deferred Compensation Arrangement with Individual, Shares Issued (in shares)			38,992
Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $				$ 178,021	$ 189,146	$ 267,031	$ 1,112,626	$ 1,591,055		$ 0
Fair Value Adjustment of Warrants | $						$ (267,031)	$ (1,112,626)		$ (1,591,055)	$ 1,084,052
The 2016 Notes [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)													0.152268
Warrants and Rights Outstanding | $											$ 7,395
Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $	$ 19,000,000
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Notes [Member]
Warrants and Rights Outstanding, Measurement Input											0.0036
Measurement Input, Price Volatility [Member] | The 2016 Notes [Member]
Warrants and Rights Outstanding, Measurement Input											1.26
Measurement Input, Expected Term [Member] | The 2016 Notes [Member]
Warrants and Rights Outstanding, Measurement Input											1.4
Measurement Input, Expected Dividend Rate [Member] | The 2016 Notes [Member]
Warrants and Rights Outstanding, Measurement Input											0
Private Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding | $									$ 372,730
Derivative Liability, Measurement Input									2.89
Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $									$ 1,591,055
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input									0.0111
Private Warrants [Member] | Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input									0.730
Private Warrants [Member] | Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input									3.96
Private Warrants [Member] | Measurement Input, Exercise Price [Member]
Derivative Liability, Measurement Input									11.50
Public Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				126,268		126,268			126,268	6,325,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1		1			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 11.50		$ 11.50				$ 11.50
Class of Warrant or Right, Redemption Price Per Share (in dollars per share) | $ / shares				0.01		0.01			$ 0.01
Threshold Closing Price for Specified Number of Trading Days (in dollars per share) | $ / shares				21		$ 21			$ 21
Threshold Trading Days for Sale of Shares (Day)						20 days			20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)						30 days			30 days
Warrants and Rights Outstanding | $									$ 1,279,182
Private Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										556,313
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 11.50		$ 11.50
Fair Value Adjustment of Warrants | $				$ 178,021		$ 267,031
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input				2.99		2.99
Private Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				90.3		90.3
Private Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input				3.46		3.46
Pre-Funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600				5,066,600		5,066,600		1,033,300
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.0001
Proceeds from Issuance of Warrants | $	$ 19,000,000								$ 103
Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 4.125
Class of Warrant or Right, Exercised During Period (in shares)						0			23,849
Proceeds from Issuance of Warrants | $									$ 98,378
The 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												120,456
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 22.99
Warrants and Rights Outstanding | $												$ 1,178,182
Warrants and Rights Outstanding, Term (Year)												5 years
The 2020 Warrants [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input												2.25
The 2020 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input												0.0028
The 2020 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input												1.26
The 2020 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input												3
The 2020 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input												0
The 2016 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													5,812
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 42.29
Warrants and Rights Outstanding | $													$ 101,000
The 2016 Warrants [Member] | General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $										$ 94,175

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details) - The 2020 Warrants [Member]	Jul. 31, 2020
Measurement Input, Share Price [Member]
Warrant, assumptions	2.25
Measurement Input, Expected Term [Member]
Warrant, assumptions	3
Measurement Input, Risk Free Interest Rate [Member]
Warrant, assumptions	0.0028
Measurement Input, Expected Dividend Rate [Member]
Warrant, assumptions	0
Measurement Input, Price Volatility [Member]
Warrant, assumptions	1.26

Note 11 - Stock Option Plan a_3

Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	192,898		192,898	192,898	65,471	112,932
Share-based Payment Arrangement, Expense	$ 39,876	$ 17,089	$ 79,562	$ 106,713	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 201,835		$ 201,835	281,397	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments				$ 0
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate				0%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			0	127,427	0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				6 years 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				93.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.31%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				5 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				87.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				0.95%
Equity Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				65,471
Equity Incentive Plan 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				1,384,761
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase				10%
Equity Incentive Plan 2020 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)				1,384,761

Note 11 - Stock Option Plan a_4

Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Beginning balance, number of shares outstanding (in shares)	192,898	65,471	112,932
Beginning balance, weighted average exercise price per share (in dollars per share)	$ 8.46	$ 16.86	$ 15.37
Number of options outstanding, options cancelled (in shares)	0		(47,461)
Options cancelled, weighted average exercise price per share (in dollars per share)			$ 0
Number of options outstanding, options granted (in shares)	0	127,427	0
Options granted, weighted average exercise price per share (in dollars per share)		$ 4.14
Ending balance, number of shares outstanding (in shares)	192,898	192,898	65,471
Ending balance, weighted average exercise price per share (in dollars per share)	$ 8.46	$ 8.46	$ 16.86
Vested and expected to vest (in shares)	192,898	192,898
Vested and expected to vest, weighted average exercise price per share (in dollars per share)	$ 8.46	$ 8.46
Share-Based Payment Arrangement, Option [Member]
Beginning balance, number of shares available for grant (in shares)	1,257,334	461,587	343,871
Number of shares available for grant, options authorized (in shares)		923,174	461,587
Number of shares available for grant, options cancelled (in shares)			47,461
Effect of plan amendment on business combination (in shares)			(391,332)
Number of shares available for grant, options granted (in shares)		(127,427)
Ending balance, number of shares available for grant (in shares)	1,257,334	1,257,334	461,587

Note 11 - Stock Option Plans an

Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Options outstanding (in shares)	192,898	192,898	65,471	112,932
Weighted average remaining contractual life (Year)	6 years 3 months 7 days	6 years 9 months 3 days
Shares exercisable (in shares)	112,744	95,803
Weighted average exercise price (in dollars per share)	$ 11.51	$ 8.46
Range 1 [Member]
Options outstanding (in shares)		48,724
Weighted average remaining contractual life (Year)		10 months 6 days
Shares exercisable (in shares)		48,724
Weighted average exercise price (in dollars per share)		$ 11.89
Range 2 [Member]
Options outstanding (in shares)		16,747
Weighted average remaining contractual life (Year)		2 years 11 months 4 days
Shares exercisable (in shares)		16,747
Weighted average exercise price (in dollars per share)		$ 31.33
Range 3 [Member]
Options outstanding (in shares)		81,227
Weighted average remaining contractual life (Year)		9 years 3 months 21 days
Shares exercisable (in shares)		17,832
Weighted average exercise price (in dollars per share)		$ 4.38
Range 4 [Member]
Options outstanding (in shares)		46,200
Weighted average remaining contractual life (Year)		9 years 10 months 20 days
Shares exercisable (in shares)		12,500
Weighted average exercise price (in dollars per share)		$ 3.72

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Corporate Office Lease [Member]
Lessee, Operating Lease, Term of Contract (Month)	12 months	12 months
Lessee, Operating Lease, Monthly Lease Payment	$ 1,300	$ 1,200
Lessee, Operating Lease, Renewal Term (Month)		12 months
Minimum [Member]
General Product Liability Insurance	$ 5,000,000	$ 5,000,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - H.C. Wainwright & Co [Member] - The Market Offering Agreement "ATM Agreement" [Member] - USD ($) shares in Thousands, $ in Millions	1 Months Ended
	Jan. 31, 2022	Jun. 30, 2022
Sale of Stock Agreement, Maximum Aggregate Gross Proceeds	$ 12.9
Shares, Issued, Ending Balance (in shares)		0
Subsequent Event [Member]
Sale of Stock Agreement, Maximum Aggregate Gross Proceeds	$ 12.9
Shares, Issued, Ending Balance (in shares)	0

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		11 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 13, 2021	Dec. 31, 2021	Dec. 31, 2020
Working Capital Deficit	$ 16,200,000		$ 16,200,000
Retained Earnings (Accumulated Deficit), Total	(79,537,681)		(79,537,681)			$ (66,831,969)	$ (58,310,093)
Cash	19,400,000		19,400,000
Net Income (Loss) Attributable to Parent, Total	$ (5,340,704)	$ (1,608,407)	$ (12,705,712)	$ (2,557,707)	$ (8,521,876)	$ (8,521,876)	$ (3,783,388)

Note 3 - Public Offering (Det_2

Note 3 - Public Offering (Details Textual) - USD ($)		3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 01, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Proceeds from Issuance or Sale of Equity, Net			$ 0	$ 31,497,463
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,133,400		4,133,400	4,133,400
Public Offering [Member]
Number of Units, One, Issued (in shares)	4,133,400
Number of Units, Two, Issued (in shares)	5,066,600
Shares Issued, Price Per Share, One (in dollars per share)	$ 3.75
Shares Issued, Price Per Share, Two (in dollars per share)	$ 3.7499
Proceeds from Issuance or Sale of Equity, Net	$ 31,500,000
Payments of Stock Issuance Costs	$ 3,000,000
Public Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	4,133,400
Over-Allotment Option [Member]
Number of Units, One, Issued (in shares)	1,200,000
Pre-Funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600	5,066,600		5,066,600	1,033,300
Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000

Note 4 - At the Market Offeri_2

Note 4 - At the Market Offering (Details Textual) - H.C. Wainwright & Co [Member] - The Market Offering Agreement "ATM Agreement" [Member] - USD ($) shares in Thousands, $ in Millions	1 Months Ended
	Jan. 31, 2022	Jun. 30, 2022
Sale of Stock Agreement, Maximum Aggregate Gross Proceeds	$ 12.9
Shares, Issued, Ending Balance (in shares)		0

Note 5 - Loss Per Share - Sched

Note 5 - Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Antidilutive securities (in shares)	15,076,630	15,030,430	15,076,630	15,030,430
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	192,898	146,698	192,898	146,698	192,898	65,471
Warrant [Member]
Antidilutive securities (in shares)	13,883,732	13,883,732	13,883,732	13,883,732	13,883,732	7,007,581
Earn-out Shares [Member]
Antidilutive securities (in shares)	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)		6 Months Ended	12 Months Ended
	Jun. 01, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Public Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		6,325,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 11.50			$ 11.50
Class of Warrant or Right, Redemption Price Per Share (in dollars per share)		0.01	$ 0.01
Threshold Closing Price for Specified Number of Trading Days (in dollars per share)		$ 21	$ 21
Threshold Trading Days for Sale of Shares (Day)		20 days	20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)		30 days	30 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		126,268	126,268		6,325,000
Warrants and Rights Outstanding			$ 1,279,182
Private Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		556,313
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 11.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					556,313
Pre-Funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	5,066,600		1,033,300	5,066,600
Proceeds from Issuance of Warrants	$ 19,000,000		$ 103
Investor Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 4.125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,900,000
Proceeds from Issuance of Warrants			$ 98,378
Class of Warrant or Right, Exercised During Period (in shares)		0	23,849

Note 7 - Stock Option Plan an_3

Note 7 - Stock Option Plan and Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expense	$ 39,876	$ 17,089	$ 79,562	$ 106,713	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 201,835		$ 201,835	$ 281,397	$ 0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			0	127,427	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)			0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)			0		47,461

Note 7 - Stock Option Plan an_4

Note 7 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Options outstanding (in shares)	192,898	192,898	65,471	112,932
Beginning balance, weighted average exercise price per share (in dollars per share)	$ 8.46	$ 8.46	$ 16.86	$ 15.37
Weighted average remaining contractual life (Year)	6 years 3 months 7 days	6 years 9 months 3 days
Vested and expected to vest (in shares)	192,898	192,898
Vested and expected to vest, weighted average exercise price per share (in dollars per share)	$ 8.46	$ 8.46
Vested and expected to vest, weighted average remaining contractual term (Year)	6 years 3 months 7 days
Shares exercisable (in shares)	112,744	95,803
Weighted average exercise price (in dollars per share)	$ 11.51	$ 8.46
Options exercisable, weighted average remaining contractual term (Year)	4 years 3 months 18 days
Share-Based Payment Arrangement, Option [Member]
Beginning balance, number of shares available for grant (in shares)	1,257,334	1,257,334	461,587	343,871

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Corporate Office Lease [Member]
Lessee, Operating Lease, Term of Contract (Month)	12 months	12 months
Lessee, Operating Lease, Monthly Lease Payment	$ 1,300	$ 1,200
Minimum [Member]
General Product Liability Insurance	$ 5,000,000	$ 5,000,000

Note 9 Fair Value Measurement_2

Note 9 Fair Value Measurements (Details Textual)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Share Price (in dollars per share) | $ / shares	$ 1.10	$ 1.10
Fair Value Adjustment of Warrants		$ (267,031)	$ (1,112,626)	$ (1,591,055)	$ 1,084,052
Private Warrants [Member]
Warrants and Rights Outstanding, Fair Value	$ 105,699	$ 105,699
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 11.50	$ 11.50
Fair Value Adjustment of Warrants	$ 178,021	$ 267,031
Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	2.99	2.99
Private Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	90.3	90.3
Private Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3.46	3.46

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements - Fair Value Assets Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Warrant liability	$ 105,699	$ 372,730
Total	105,699	372,730
Fair Value, Inputs, Level 3 [Member]
Warrant liability	105,699	372,730
Total	$ 105,699	$ 372,730

Note 9 - Fair Value Measureme_2

Note 9 - Fair Value Measurements - Fair Value Liabilities Measured on Recurring Basis Unobservable Input Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Balance, beginning of period	$ 283,720	$ 1,040,305	$ 372,730	$ 1,963,785
Change in fair value of warrant liability	(178,021)	(189,146)	(267,031)	(1,112,626)
Balance, end of period	$ 105,699	$ 851,159	$ 105,699	$ 851,159